Laurie Carr Mims

We represented Shareholder Representative Services (SRS) in its role as representative of the former shareholders of FerroKin Biosciences in a post-merger dispute with Shire Pharmaceuticals, which had refused to make a $45 million milestone payment related to the development of an experimental iron chelation drug. After a four-day bench trial, the Delaware Chancery Court entered judgment in favor of SRS, ruling in a 77-page opinion that the former FerroKin shareholders were entitled to the overdue $45 million milestone, as well as five years of interest on the payment and their attorneys’ fees and costs.

We represent Genentech in a federal trade secret theft lawsuit alleging that former Genentech scientists, several of whom have also been charged criminally by the Department of Justice, stole confidential and proprietary information to help a foreign company develop biosimilar versions of Genentech medicines.

On the eve of trial in Delaware federal court, we obtained a favorable settlement for the former CEO of a major healthcare company in a breach of fiduciary duty case. We also represented him in related insurance coverage action in Colorado federal court.

We represented a start-up drug discovery company in a collaboration agreement dispute regarding the development of a diabetes drug. We obtained a favorable settlement before arbitration was filed.

We represented a biotechnology company developing a drug for a rare genetic disease in arbitration proceedings over its rights to develop its sole product under a collaboration agreement with a large pharmaceutical company. With our assistance, on the first day of the arbitration the parties reached a favorable settlement, which provided for our client’s acquisition of the life-saving drug it is developing. The FDA has now approved the drug and our client successfully conducted an IPO.

We represented Revance, a biotechnology company which develops next-generation dermatology products and therapeutic medicines, in a Delaware Chancery Court bench trial. The trial determined Revance’s worldwide rights to its injectable botulinum toxin product, as well as its ground-breaking topical botox product. Days after the trial, we finalized a settlement which returned all global rights to develop and commercialize both products across all indications to Revance, and resolved all outstanding litigation between the companies.

We successfully defended at trial an Am Law 50 law firm and one of its former partners against a $100 million claim. The plaintiff alleged malpractice and breach of fiduciary duty related to estate planning. After an eight-week trial in California state court, we won a complete victory.

We represented a communications provider in its appeal of an adverse judgment in a sexual harassment case. We won in part and lost in part on appeal.

We represented an investment fund executive charged with criminal tax fraud related to a tax-shelter transaction that the fund designed and implemented. We resolved the matter by negotiating a plea to reduced charges.